Company Filing History:
Years Active: 1993-2003
Title: The Innovations of Robert Franciscus Van Ginckel
Introduction: Robert Franciscus Van Ginckel, an inventive mind hailing from Vorselaar, Belgium, has made significant contributions to the field of pharmaceuticals. With two patents to his name, he has focused on developing innovative methods and compounds for treating cancer.
Latest Patents: Van Ginckel's latest patents include "Farnesyl Protein Transferase Inhibitors with In Vivo Radiosensitizing Properties." This groundbreaking invention identifies that farnesyl protein transferase inhibitors possess radiosensitizing properties, making them valuable for preparing pharmaceutical compositions to administer before, during, or after tumor irradiation for effective cancer treatment. His second patent, "Compounds, Compositions and Anti-Neoplastic Methods," details a method for treating neoplasms in mammals by using a specific alkyl carbamate compound, as well as the pharmaceutical compositions containing this active ingredient.
Career Highlights: Robert Van Ginckel has built his career at Janssen Pharmaceutica NV, a well-regarded company in the pharmaceutical industry known for its innovative research and development. His contributions reflect a strong commitment to advancing medical treatments, particularly in cancer care.
Collaborations: Throughout his career, Van Ginckel has collaborated with esteemed colleagues such as Wim Joanna Floren and David William End. These partnerships underscore the importance of teamwork and collaboration in driving forward the scientific endeavors related to pharmaceuticals.
Conclusion: Robert Franciscus Van Ginckel stands out as a notable inventor whose work in developing cancer treatment methods is changing the landscape of oncology. His patents exemplify how innovative ideas can lead to practical applications that benefit healthcare and improve patient outcomes.